Home
News
Latest News
People Moves
Business Briefs
Newsletters
Features
Features
Reprints
Surveys
Editorial Calendar
Web Exclusives
Issue Archive
Events
MM&M Awards 2012
txt4pharma
MM&M Virtual Summit
Webcasts
Leadership Exchanges
Whitepapers
Directories
Creative Portfolio
Mobile Guide
Interactive Guide
Pharmaceutical Marketers Directory
MM&M Service Directory
Agency Gallery
Direct Marketing Showcase
Medical Education Review
Sales Force Listings
Jobs
About Us
Subscriber Services
Contact Us
Media Information
Editorial Advisory Board
Drug Info
New Drug Dossier
Drug Database
Subscribe
Order Now
Subscriber Services
Newsletters
RSS
|
Login
|
Register
MMM
>
News
> Shire awards Unit 7 consumer business for ADHD patch
DTC Report
Shire awards Unit 7 consumer business for ADHD patch
July 01, 2006
Print
Email
Reprint
Permissions
Text:
A
|
A
|
A
More News
POM aims arch ads at FTC tormentors
Xarelto gets no love from FDA panel
Did FDA's Vytorin warning negatively impact health outcomes?
Roundtable outlines path for publisher, pharma credibility
No-see docs are know-nothings when it comes to new drug info, study suggests
Shire has awarded Unit 7 the consumer business for its Daytrana ADHD patch. Ads and relationship marketing from the Omnicom firm will break later this year.
From the July 2006 Issue of MMM
Please enable JavaScript to view the
comments powered by Disqus.
Video Exclusive
Web Exclusives
Five industry experts advise specialty pharma company on digital strategy
April 20, 2012
Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
MM&M Awards 2011 HIghlights
The Best MM&M Awards Ever!
MAHF Ceremony 2012
Photos from the Medical Advertising Hall of Fame Awards ceremony
Most Popular
Most Emailed
Most Recent
Goodbye Plavix, hello competition
No-see docs are know-nothings when it comes to new drug info, study suggests
Pharmas are from Mars, Payers are from Venus
Study: Young Latinas are key decision makers, prefer English
How CDC's hep.-C testing advice benefits drugmakers now
Roundtable outlines path for publisher, pharma credibility
Did FDA's Vytorin warning negatively impact health outcomes?
Xarelto gets no love from FDA panel
PhRMA's Washington wish list
E-prescriptions boost adherence data
Study: Young Latinas are key decision makers, prefer English
No-see docs are know-nothings when it comes to new drug info, study suggests
Pharmas are from Mars, Payers are from Venus
E-prescriptions boost adherence data
How CDC's hep.-C testing advice benefits drugmakers now
Goodbye Plavix, hello competition
Roundtable outlines path for publisher, pharma credibility
PhRMA's Washington wish list
Xarelto gets no love from FDA panel
Did FDA's Vytorin warning negatively impact health outcomes?
POM aims arch ads at FTC tormentors
Xarelto gets no love from FDA panel
Did FDA's Vytorin warning negatively impact health outcomes?
Roundtable outlines path for publisher, pharma credibility
No-see docs are know-nothings when it comes to new drug info, study suggests
E-prescriptions boost adherence data
How CDC's hep.-C testing advice benefits drugmakers now
PhRMA's Washington wish list
Study: Young Latinas are key decision makers, prefer English
Pharmas are from Mars, Payers are from Venus
Popular Topics
Acquisition
Adherence
Advertising
App
Celebrity
Clinical Trial
Co-Marketing
Diabetes
Diagnostics
Digital
Direct To Consumer (DTC)
Disease Awareness
Downsize
DTC
Education & Awareness
FDA
Food
FTC
Government
Guidance
Health Plans
HMOs
Hospitals
Marketing Research
Sales Force